|
 |
StalevoThis page contains recent news articles, when available, and an overview of Stalevo but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Stalevo's clear convenience and compliance benefit will see the combination therapy emerge as the market leading brand between 2011 and 2013. ... PR-inside.com (press release) Wild West City gunshot victim recovering - slowly, and with determination - Dec 29, 2009 She said his speech has improved over the past 18 months, ever since he started taking Stalevo, a drug used to treat Parkinson's disease. ... Dailyrecord.com Parkinson's Disease - Drug Pipeline Analysis and Market Forecasts to 2015 - Dec 22, 2009 This is followed by Glaxo's Requip/Requip XL and Orion/Novartis' Stalevo. Boehringer Ingelheim, GlaxoSmithKline (GSK), Orion/Novartis, Teva/Lundbeck remain ... Online PR News (press release) BRIEF-Orion pulls US application to extend Stalevo use - Oct 21, 2009 ...says withdrawal is based on asessment of findings from clinical studies, which indicate shat Stalevo does not provide a consistent risk/benefit profile for ... Forbes Orion Group Interim Report January-September 2009 - Oct 26, 2009 Deliveries of the Parkinson's disease drugs Stalevo and Comtan to Novartis and sales of Simdax heart failure drug, Easyhaler pulmonary drugs and Precedex ... Trading Markets (press release) Research and Markets: Commercial Insight: Parkinson's Disease - Japan and ... - Oct 28, 2009 Highlights of this title: * Stalevo's clear convenience and compliance benefit will see the combination therapy emerge as the market leading brand between ... Reuters Orion net profit up to EUR118.4m in 9-mo '09 - Oct 26, 2009 Sales of Orion's Parkinson's disease drugs Stalevo and Comtan increased to EUR182.2m from EUR155.7m. Sales of the Easyhaler product for the treatment of ... Therapeutics Daily (press release) (registration) Hi vá»?ng má»›i cho bệnh nhân Parkinson - Oct 31, 2009 Vì thế có sá»± ra Ä‘á»?i của Stalevo. Trong Stalevo có sá»± kết hợp giữa ba thà nh phần carpidopa, levodopa và entacapone. Carbidopa ức chế quá trình khá» carboxy ... Tuổi Trẻ Novartis study shows Parkinson's drug controls symptoms more than … - Apr 15, 2008 Stalevo is indicated for certain Parkinson's disease patients who ... Stalevo is a levodopa therapy combining levodopa and carbidopa with the enzyme ... Forbes Orion mulling legal options to protect patents on Stalevo in US - Oct 1, 2007 HELSINKI (Thomson Financial) - Orion said it is considering legal action to protect its patents on Stalevo, its drug treatment for Parkinson's Disease, ... Forbes Finland's Orion files US suit to protect key drug - Dec 8, 2008 ...'Stalevo is an enhanced levodopa treatment originated by Orion Corporation and marketed in the United States by its exclusive licensee, Novartis (nyse: NVS ... Forbes Orion's Stalevo drug passes initial Phase III study - Jan 24, 2008 HELSINKI, Jan 24 (Reuters) - Finland's Orion (ORNBV.HE) said on Thursday its partner Novartis (NOVN.VX) had informed the drug company of a first-step ... Reuters UK Stalevo.(drug overview)(Drug overview) - Dec 1, 2005 Stalevo is used to help relieve symptoms of Parkinson's disease, including tremors, muscle stiffness and rigidity, slowness of movement, and poor balance or ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com New evidence demonstrates early use of Stalevo® improves … - Oct 31, 2006 Kyoto, October 31, 2006 – New data shows that Stalevo* significantly improves quality of life in patients with Parkinson's disease with no or minimal motor ... webwire.com UPSATE 1-Orion studies options to protect patent in US - Jan 2, 2008 Stalevo is an enhanced levodopa treatment and is marketed in the United States by Novartis (NOVN.VX: Quote, Profile, Research), its exclusive licensee. ... Reuters India Stalevo 50 Oral : Uses, Side Effects, Interactions, Pictures,... - Aug 10, 2006 This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or ... WebMD FDA Approves New Dosage Strength Of Stalevo(R) For People With … - Aug 8, 2007 Novartis Pharmaceuticals Corporation announced that the US Food and Drug Administration (FDA) has approved a new higher dose strength of Stalevo(R) ... Medical News Today - Medical News Today (press release) NORDIC STOCKS - Factors to watch on Nov 3 - Nov 3, 2008 ...is 'currently evaluating its legal options' to protect its rights. It said generic competition for Stalevo is neither certain nor imminent. Forbes ORION/LAWSUITS - Feb 8, 2008 The Indian company was seeking to market generic versions of its Parkinson's disease Stalevo tablets, Orion said in a statement. ... Reuters … dose of Novartis' Stalveo cleared in USA.(drug approval for Stalevo... - Aug 13, 2007 The approval of Stalevo 200mg, which consists of 50mg carbidopa, 200mg levodopa, ... Stalevo simplifies treatment because it combines levodopa, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Stalevo - Levodopa / Carbidopa / Entacapone - Medical Drug - Jul 1, 2008 Stalevo is a medicine used to relieve the symptoms of Parkinson's disease in patients who are inadequately controlled by other therapies. ... Virtual Medical Centre - The Virtual Medical Centre Stalevo approved in higher dose.(FYI)(Brief article) - Sep 1, 2007 The Parkinson disease drug Stalevo (carbidopa, levodopa, and entacapone) is now approved in a higher 200-mg dose indicated to help minimize the end of dose. $4.95 - Clinical Psychiatry News - ECNext New evidence obtained on Stalevo for Parkinson's disease: Novartis. - Nov 27, 2006 Research indicating that the quality of life for patients with Parkinson's disease is improved with the administration of Stalevo (levodopa + carbidopa + ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Stalevo approved in higher dose.(FYI)(Brief article) | Article from... - Sep 1, 2007 Stalevo approved in higher dose.(FYI)(Brief article) ... find Clinical Psychiatry News articles. The Parkinson disease drug Stalevo (carbidopa, levodopa, ... Pay-Per-View - Clinical Psychiatry News - HighBeam Research STALEVO Orion conducting phase III trial. - Apr 10, 2006 Orion and Novartis are conducting a phase III trial, called STRIDE-PD, to investigate if STAVELO can delay the onset of motor complications, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Orion/Novartis' Stalevo fares well in Ph III trial.(Medical condition... - Feb 4, 2008 Finnish drugmaker Orion has been informed by its marketing partner Swiss drug major Novartis of the positive outcome of FIRST-STEP, a Phase III study in 423 ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Higher dose of Stalevo.(PRODUCTS)(Brief article) | Article from... - Nov 1, 2007 Higher dose of Stalevo.(PRODUCTS)(Brief article) ... find Internal Medicine News articles. The Parkinson disease drug Stalevo (carbidopa, levodopa, ... Pay-Per-View - Internal Medicine News - HighBeam Research Approval for a higher dose of Stalevo (carbidopa, levodopa, and … - Sep 3, 2007 Approval for a higher dose of Stalevo (carbidopa, levodopa, and entacapone) has been granted to Novartis Pharmaceuticals, East Hanover, NJ, (862) 778-8300. $4.95 - Drug Topics - ECNext Stalevo.(FDA actions in brief) - Sep 1, 2007 A new dosage strength of carbidopa, levodopa, and entacapone (Stalevo, Novartis) was approved for the treatment of Parkinson disease (PD) in patients with ... $4.95 - Formulary - ECNext CORRECTION: Novartis' Stalevo. - Aug 13, 2007 In the Wednesday August 8 update to our web site, the headline to our article about Stalevo, Novartis' Parkinson's disease drug which has just had a higher ... $4.95 - Pharma Marketletter - ECNext Orion Profit Falls Short of Estimates as Costs Rise - Aug 5, 2008 Orion gets about one-third of its revenue from Stalevo and Comtan, ... Stalevo sales increased 32 percent to 37.8 million euros, while revenue from Comtan ... Bloomberg … sykdommer/medisiner: jeg har parkinsson, og bruker sifrol og stalev... - Apr 6, 2006 Stalevo kan gi munntørrhet, Sifrol skal ikke gi symptomer derfra. Jeg tror ikke medisinene er Ã¥rsaken til sikling, det kan tenkes at det er parkinson i seg ... Lommelegen.no ORION: STÄMMER SUN FÖR PATENTINTRÃ…NG PÃ… STALEVO - Nov 13, 2007 STOCKHOLM (Direkt) Det finska läkemedelsbolaget Orion har stämt Sun Pharmaceutical för patentintrÃ¥ng i USA pÃ¥ Stalevo, för behandling av Parkinsons sjukdom. ... Dagens Nyheter Parkinson's medicine in patent tangle - Nov 4, 2008 Drug major Wockhardt has challenged the US patent of Stalevo, a new generation ... Stalevo simplifies the treatment process by combining levodopa, ... Rediff Novartis: Stalevo wirkt besser gegen Parkinson als Levodopa - Apr 15, 2008 BASEL (Dow Jones)--Das Novartis-Mittel Stalevo zeigt einer Studie zufolge eine bessere Wirkung bei Patienten mit früher Parkinson-Krankheit als die bislang ... FinanzNachrichten.de Parkinson's disease is a complex neurological dis-order with cardinal... - Jul 8, 2005 A recently introduced preparation, Stalevo, combines levodopa with a dopa ... Patients should be told that entacapone and Stalevo might cause staining of ... Pay-Per-View - Practice Nurse - Factiva, from Dow Jones Q1 2006 Orion Corporation Earnings Conference Call - Final. - May 8, 2006 Regarding the Comtess compound and Stalevo, this was an exceptional quarter ... And the Entacapone lifecycle management with the Stalevo product currently ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com … .- Un estudio demuestra la superioridad de 'Stalevo' (Novartis) en... - Apr 28, 2008 ...'Stalevo' está indicado actualmente para ciertos pacientes con enfermedad de Parkinson que experimentan fluctuaciones motoras (de los movimientos) a ... ecodiario åˆºæ¿€ç¥žç¶“è£½é€ å¤šå·´èƒºStalevoæ²»æŸ?金森æ°?ç—‡ - May 2, 2007 ...（å?‰éš†å?¡è¨Šï¼‰æŸ?金森æ°?症（Parkinson's Disease，PD）是一種慢性腦部退化性疾病，主è¦? 是腦內的多巴胺（dopamine）ä¸?足，引起行動障礙å•?題。 ... é¦¬ä¾†è¥¿äºžå…‰æ˜Žæ—¥å ± Finnish Orion sues Sun Pharmaceuticals in US - Nov 13, 2007 BO), which is seeking to market generic versions of Orion's Stalevo tablets. Stalevo is an enhanced levodopa treatment and is marketed in the United States ... Reuters Orionilta reilu osinko - Feb 6, 2007 Orionin omat Parkinson-lääkkeet Stalevo ja Comtess/Comtan (entakaponi) ... Stalevo- ja Comtan-toimitukset markkinointipartneri Novartikselle olivat yhteensä ... Arvopaperi Online OUTI JÄRVINEN/KL-ARKISTO - Feb 16, 2005 Stalevo etenee markkinoilla hyvin. Sen mukaantulo on kaikilla markkinoilla lisännyt entakaponin markkinaosuutta noin 50 prosenttia, Yhdysvalloissa jopa ... Kauppalehti - Kauppalehti Un traitement moderne pour la maladie de Parkinson améliore le bien- … - Sep 18, 2008 Stalevo* permet de traiter de façon efficace l'épuisement de l'effet thérapeutique ... Stalevo* est aussi indiqué en remplacement de la lévodopa-carbidopa à ... LeLézard.com Orion files suit against Wockhardt - Dec 12, 2008 ..."Stalevo is an enhanced levodopa treatment originated by Orion Corporation and marketed in the United States by its exclusive licensee Novartis [Get Quote] ... Rediff Pharmacy update - Parkinson's disease: a case study.(Case study) - Jan 27, 2007 He also "hated" the Stalevo as he felt the start of his constipation had coincided with ... Levodopa (in Sinemet and Stalevo) is a precursor of dopamine. ... Free with registration - Chemist & Druggist - AccessMyLibrary.com High-dose Lotrel approved.(PRODUCTS)(Brief article) | Article from … - Oct 15, 2006 Article: Higher dose of Stalevo.(PRODUCTS)(Brief article) Internal Medicine News; November 1, 2007 ; 611 words ... ... higher 200-mg dose indicated to help ... Pay-Per-View - Internal Medicine News - HighBeam Research Femara approved as initial Tx.(drug approval)(Brief article) |... - Apr 1, 2006 Article: Higher dose of Stalevo.(PRODUCTS)(Brief article) Internal Medicine News; November 1, 2007 ; 611 words ... ... higher 200-mg dose indicated to help ... Pay-Per-View - Internal Medicine News - HighBeam Research Press Release: Once-Daily AGILECT(R) Demonstrated Improvement in … - Mar 10, 2005 Comtess/Stalevo and Teva Pharmaceuticals/Lundbeck's Agilect/Azilect. According to the report, market sales will also ... ADAGIO trial demonstrated the ... Pay-Per-View - PR Newswire - HighBeam Research Orion profit beats forecasts, shares rise - Apr 25, 2008 Currently Stalevo is indicated for use in patients whose treatment with levodopa is no longer enough to maintain full control of symptoms until the next ... Reuters Orion sues Sun Pharmaceuticals to protect patent on Parkinson's... - Nov 14, 2007 Like Comtan, Stalevo is marketed in the US exclusively by licensee Novartis, the Swiss pharmaceuticals giant. Orion said that, together with Novartis, ... ABCmoney.co.uk Parkinson's Disease Candidate Meets Primary Endpoint - Jan 30, 2008 A Novartis-sponsored Phase III trial with Stalevo, a potential treatment for Parkinson's disease, ... The patients received three daily doses of Stalevo ... FDA news - FDA news (subscription) Q2 2007 Orion Corporation Earnings Conference Call - Final. - Aug 6, 2007 And then, secondly, on the lifecycle management for Stalevo, which seems to be in the pipeline along with the new molecule on your COMT inhibitor. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Finland's Orion sues Wockhardt over Parkinson's drug - Sep 12, 2008 With an eye on selling a generic version of Stalevo in the US, Wockhardt had filed a an abbreviated new drug appliaction with the US Food and Drug ... Newsroom Finland Orion comments on new challenge by Sun Pharmaceutical Industries... - Jan 4, 2008 Stalevo is an enhanced levodopa treatment originated by Orion Corporation and marketed in the United States by its exclusive licensee, Novartis, ... chemie.de Press Release: Orion Pharma Selects ChemDiv as A Partner in Drug … - Nov 30, 2007 Stalevo(R) and Comtess(R) / Comtan(R), treatments originated by Orion for ... Stalevo, developed by Orion Pharma, is marketed by Novartis and Orion Pharma ... Pay-Per-View - PR Newswire - HighBeam Research Orion in patent row with Sun - Nov 14, 2008 Orion filed a similar suit against Sun last year over the generic version of Orion's another medicine, Stalevo. Sun's application had challenged the ... Rediff COMT inhibitors for Parkinson's disease - Dec 8, 2008 A combination medicine (Stalevo) is available that combines entacapone, levodopa, and carbidopa. This may be more convenient for some people because they ... WebMD Crunch Time at Teva - Aug 1, 2005 Novartis (NVS - commentary - Cramer's Take) offers two COMT inhibitors -- Comtan and Stalevo, which combines Comtan with levodopa/carbidopa. ... TheStreet.com - TheStreet.com (subscription) Factiva Search - Oct 31, 2006 New evidence demonstrates early use of Stalevo improves quality of life and may ... Kyoto, October 31, 2006 - New data shows that Stalevo[1] significantly ... Pay-Per-View - Hugin Press Release - Factiva, from Dow Jones Crunch Time at Teva - Aug 4, 2005 Novartis (NVS:NYSE) offers two COMT inhibitors -- Comtan and Stalevo, which combines Comtan with levodopa/carbidopa. Several companies are conducting ... TheStreet.com - TheStreet.com (subscription) Orion Pharma sees 37% hike in 2005 profits.(Orion Pharmaceuticals )( … - Feb 20, 2006 The firm's R&D expenditure increased slightly to 76.5 million euros, with the firm's STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation) trial of Stalevo ... $4.95 - Pharma Marketletter - ECNext Parkinson's and me - Apr 3, 2007 I take a thing called Stalevo every day. I take four of them, small, oblong, ... Stalevo is relatively new. There are others. Some are old and reliable. ... Roanoke Times Press Release: More Than 80% of People With Parkinson's Disease … - Jun 13, 2006 PR Newswire Europe; October 26, 2004 ; 700+ words ... ... announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation . ... Pay-Per-View - PR Newswire Europe - HighBeam Research Vt. psychiatrists unduly influenced.(POLICY & PRACTICE) | Article... - Aug 1, 2008 Article: Stalevo approved in higher dose.(FYI)(Brief article) Clinical Psychiatry News; September 1, ... Stalevo is made by Novartis Pharmaceuticals Corp. ... Pay-Per-View - Clinical Psychiatry News - HighBeam Research Article: Feeding-Tube Benefit Questioned; Experts: Device Unlikely to... - Apr 1, 2005 Biotech Week; October 15, 2003 ; 700+ words ... ... announced that a new treatment for Parkinson disease, Stalevo (carbidopa, levodopa ... therapy ... Pay-Per-View - Washington Post - HighBeam Research Gurutz Linazasoro - Apr 11, 2008 Hasta hace 2 años, mi calidad de vida era bastante aceptable, ahora por el contrario la medicación no me hace el mismo efecto, tomo Stalevo, 110/125 y los ... elmundo.es Medialink Features: Using a Diary Card to Manage Parkinson's Disease ... - Feb 15, 2007 Stalevo is one of the most recent advancements in levodopa therapy since the introduction of levodopa/carbidopa in the 1970s. ... Free with registration - PR Newswire - AccessMyLibrary.com New PBS drugs to help older Australians - Apr 1, 2005 Stalevo is more convenient for those affected by Parkinson's disease because it is one tablet that combines three drugs - levodopa, carbidopa and entacapone ... The Age Orion haastaa Sun Pharmaceuticalsin - Nov 14, 2007 Tehostettu levodopahoito Stalevo on Orionin alkuperälääke Parkinsonin tautiin. Orion Oyj:n lisenssikumppani Novartis markkinoi sitä Yhdysvalloissa ... MediUutiset Orion puolustaa Stalevoa oikeudessa Yhdysvalloissa - Dec 9, 2008 Tavoitteena on puolustaa Stalevo-alkuperälääkettä suojaavia patentteja. ... Stalevo on Parkinsonin taudin hoitoon tarkoitettu alkuperäislääke. ... MediUutiset Buone notizie per i malati di Parkinson - May 10, 2006 Prendendo Stalevo nelle fasi iniziali si evita questo problema. Ma anche chi è già a uno stadio medio- grave e sta seguendo la vecchia terapia può passare ... Donna Moderna Tanker om en operasjon - Sep 9, 2008 Etter operasjonen skulle jeg daglig ta 3 - 4 Stalevo (100mg levodopa). ... Jeg hadde fÃ¥tt beskjed om at jeg kunne ta 3 tabletter kalt stalevo. ... TV2 - TV 2 Press Release: Central Nervous System Parkinson Disease Report … - Sep 18, 2007 Pain & Central Nervous System Week; October 13, 2003 ; 700+ words ... ... announced that a new treatment for Parkinson disease, Stalevo (carbidopa, ... Pay-Per-View - M2 Presswire - HighBeam Research Parkinson's Disease Market analysis and forecasts, 2008- 2012, 2017 &... - Jan 8, 2008 Stalevo Combination Therapy Drives Sales. Growth. Major Market Analysis. 5.1. Major Markets Experience Year-on-Year. Revenue Expansion ... $4,422.00 - VISIONGAIN A - Alacra Store Barnie Day: A decade with Parkinson's Disease - Feb 21, 2007 I take a thing called Stalevo every day. I take four of them, small, oblong, ... Stalevo is relatively new. There are others. Some are old and reliable. ... Martinsville Bulletin La detección temprana de los sÃntomas de “deterioro de fin de dosisâ€?... - May 26, 2006 En este sentido, Gurutz Linazasoro destaca los beneficios de Stalevo®, un medicamento que combina la levodopa, la carbidopa y la entacapona, ... acceso.com Novartis Q1 net beats expectations on underlying growth, divestments ... - Apr 24, 2006 Net sales in Europe were down 7 pct in usd but rose 1 pct in local currencies with strong performances from Diovan, Glivec, Femara, Comtan/Stalevo and ... Forbes Helsinki share higher midday ahead of earning season - Apr 15, 2008 ...the number of indications for its Parkinson's disease drug Stalevo and has applied for regulatory approval in the United States and European Union. ... Forbes DJ ÃœBERBLICK/Unternehmen - 17.00 Uhr-Fassung - Apr 15, 2008 Das Novartis-Mittel Stalevo zeigt einer Studie zufolge eine bessere Wirkung ... Patienten mit frühem Parkinson könnten bei einer Behandlung mit Stalevo ihre ... financial.de Orionilta positiivisia tutkimusuutisia - Feb 6, 2007 Tutkimuksessa verrataan Stalevo-lääkehoitoa perinteiseen levodopa/karbidopa-hoitoon. Loppuvuonna 2004 käynnistynyttä, yhteistyössä markkinointipartneri ... Arvopaperi Online Toisille hyviä, toisille huonoja lääkeuutisia - Feb 26, 2007 Tutkimuksessa verrataan Stalevo-lääkehoitoa perinteiseen levodopa/karbidopa-hoitoon. Loppuvuonna 2004 käynnistynyttä, yhteistyössä Novartisin kanssa ... Arvopaperi Online Helsinki shares close lower, TeliaSonera falls on disappointing Q4 … - Feb 8, 2008 ...the India-based group which has filed Paragraph IV challenges to three patents covering the Finnish group's Parkinson's Disease drug Stalevo. ... Forbes Helsinki shares close higher led by Nokia on bargain-hunting UPDATE - Nov 14, 2007 The drugmaker said it has filed a lawsuit in the US against India-based group Sun Pharmaceuticals to protect a patent on Stalevo, its drug treatment for ... Forbes Orion Pharma Selects ChemDiv as A Partner in Drug Discovery Services - Nov 30, 2007 Stalevo(R) and Comtess(R) / Comtan(R), treatmentsoriginated by Orion for Parkinson 's disease, are the largest products bysales in Orion's portfolio. ... Reuters Un singur medicament nu reuseste controlul HTA - Oct 12, 2005 Pacientii care sufera de Parkinson au la dispozitie un nou produs sub forma de comprimate, denumit Stalevo sau "Tripla combinatie". Prof. dr. ... Adevărul Orion considers lawsuit to protect patent - Aug 13, 2007 Orion's two best-selling drugs for Parkinson's disease, Stalevo and Comtess/Comtan, are based on the patent of entacapone. ... Reuters Orion Q4 profit misses consensus, shares down - Feb 7, 2008 The drugmaker's key patent on entacapone, on which the company's two best-selling Parkinson's disease drugs, Stalevo and Comtess/Comtan, are based, ... Reuters A roundup of Wednesday's action on major European exchanges - Jan 2, 2008 In pharma news, ORION (+0.31%) initiated a study to protect its patent in the US regarding its Parkinson's medication Stalevo. In other news, VESTAS WIND ... BusinessWeek Nou medicament pentru Parkinson - Sep 28, 2005 Pacientii care sufera de maladia Parkinson au la dispozitie un nou medicament, Stalevo, care poate ameliora simptomele bolii, au anuntat reprezentantii ... Evenimentul Zilei Pharmacotherapy for Parkinson's disease: current options, promising … - Aug 1, 2006 Levodopa/carbidopa/entacapone (Stalevo). Neurology. 2004;62(1 suppl 1):S64-S71. (18.) Olanow CW. Levodopa-CDS in the treatment of Parkinson's disease: the ... Free with registration - JAAPA-Journal of the American Academy... - AccessMyLibrary.com Article: Four new Parkinson's disease guidelines hailed: review finds... - Jun 1, 2006 Article: Orion's Stalevo fails to delay dyskinesia in early PD . ... Stalevo is currently indicated for the treatment of adult patients with the disease and ... Pay-Per-View - Clinical Psychiatry News - HighBeam Research Orion veti henkeä - Feb 15, 2005 Sydänlääke Simdaxin tutkimusten siirtyminen Abbot Laboratoriesille pienensi kuluja ja Parkinson-lääke Stalevo eteni suurilla markkinoilla. ... MediUutiset Levodopa medications for Parkinson's disease - Dec 8, 2008 Stalevo, a new medicine that combines entacapone, levodopa, and carbidopa. This may be more convenient for some people because they would need to take only ... WebMD Article: WORK & LIFE; Staying on the job with Parkinson's disease; … - May 3, 2007 Biotech Week; October 15, 2003 ; 700+ words ... ... announced that a new treatment for Parkinson disease, Stalevo (carbidopa, levodopa ... therapy ... Pay-Per-View - Star Tribune - HighBeam Research FPIN's Clinical Inquiries - Aug 1, 2005 ...or the combination of levodopa and carbidopa (Sinemet) or levodopa and cabidopa with entacapone (Stalevo) improves symptoms and quality of life, ... AAFP News Now Dax kann doch noch stürmen - Apr 15, 2008 Analysten die Bedeutung der Nachricht. Der Schweizer Pharmariese Novartis hat mit seinem Mittel Stalevo bei Parkinson- Patienten dagegen gut abgeschnitten. ARD Novartis profitiert von Neuheiten - May 8, 2008 So stünden etwa das Osteoporose-Mittel Aclasta und das Parkinson-Medikament Stalevo vor dem Durchbruch. Bis 2011 will das Unternehmen zudem vier neue ... Handelsblatt Nuove armi contro il Parkinson - May 13, 2006 Inoltre, è oggi disponibile lo stalevo, promettente preparato costituito, oltre che da levodopa, anche da entacapone e carbidopa, due inibitori degli enzimi ... Corriere della Sera Article: Smokers less likely to be diagnosed with disorder.(Front) -... - Jul 10, 2007 Biotech Week; October 15, 2003 ; 700+ words ... ... announced that a new treatment for Parkinson disease, Stalevo (carbidopa, levodopa ... therapy ... Pay-Per-View - Virginian-Pilot - HighBeam Research CLINICAL REVIEW: The Treatment of Parkinson's Disease - Feb 15, 2005 Stalevo is a combined product of levodopa, a decarboxylase inhibitor, and entacapone. The levodopa dose can be reduced when COMT inhibitor is added, ... RedOrbit New drugs listed on PBS. 01/04/2005. ABC News Online - Jan 4, 2005 Federal Health Minister Tony Abbott says Stalevo will help around 1000 patients with Parkinson's disease because it puts three drugs into one tablet and ... ABC Regional Online - ABC Regional Online Neljän tuloksen viikko - Aug 8, 2008 Parkinson-lääkkeet Stalevo ja Comtess/Comtan toivat liikevaihtoa 31 prosenttia lääkeliiketoiminnan liikevaihdosta. Kun ihmisille suunnattujen lääkkeiden ... MediUutiset Orionin tulos laski odotettua vähemmän - Apr 25, 2007 Parkinson-lääkkeet Stalevo ja Comtess/Comtan toivat liikevaihtoa yhteensä 54,6 miljoonaa euroa, eli noin 33 prosenttia liikevaihdosta. ... MediUutiset Orionin voitto ja osinko ylittivät odotukset - Feb 10, 2006 Orionin omat Parkinson-lääkkeet Stalevo ja Comtess/Comtan toivat kolmasosan koko Pharman liikevaihdosta. Pharman liikevaihto kasvoi kuusi prosenttia. ... Kauppalehti - Kauppalehti Orion hyvässä vedossa - Aug 8, 2006 Eniten kasssavirtaa toi tähtituote Stalevo, jonka myynti kasvoi 27 prosenttia. Orionin kaikkien lääkkeiden kokonaismyynti väheni alkuvuoden aikana yhdeksän ... MediUutiset Orionin tutkimuskulut nousevat yli 100 miljoonaan euroon - Aug 6, 2008 Parkinson-lääkkeet Stalevo ja Comtess/Comtan toivat liikevaihtoa 31 prosenttia lääkeliiketoiminnan liikevaihdosta. Kun ihmisille suunnattujen lääkkeiden ... MediUutiset Orion jäi odotuksista reilusti - Oct 28, 2008 Novartiksen varastotasojen alenemisen takia Orionin Stalevo- ja Comtan-toimitukset ovat olleet kokonaisuutena hieman edellisvuotta alhaisemmat. ... MediUutiset Orionilta ei yllätyksiä - Oct 25, 2007 Parkinson-lääkkeet Stalevo ja Comtess/Comtan toivat liikevaihtoa yhteensä 152,6 miljoonaa euroa vuoden takaiseen 137,2 miljoonaan euroon verrattuna. ... MediUutiset |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |